AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 162 min read$IONS

Kordasiewicz Holly B. sold $4.5M of IONS

Kordasiewicz Holly B. (EVP, Chief Development Officer) sold 60,846 shares of IONIS PHARMACEUTICALS INC (IONS) at an average of $73.41 ($73.09–$74.05, $4.47M total) across 2 trades on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kordasiewicz Holly B.
Published Jun 16, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IONS
Neutral
high confidence
Mentioned
$IONS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IONSNeutralLow
01

Why it matters

The disclosure adds incremental information about insider liquidity/positioning but does not introduce new operational or clinical/regulatory facts.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing reduces the likelihood of a fundamental read-through.

03

What to watch

The article provides only the sale details; it does not state whether other insiders bought, whether the company has upcoming trial/readouts, or whether the sale size is unusual relative to prior patterns.

Relevance 5/10Novelty 5/10Timing: Filed on 2026-06-16 for a sale executed 2026-06-12

Background

This is an SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals (EVP Chief Development Officer).

Company-level read

Ticker impact

$IONSNeutralHigh confidence
Context

Ionis Pharmaceuticals disclosed an EVP Chief Development Officer open-market sale of 60,846 shares at ~$73.09–$74.05 on a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with a pre-arranged 10b5-1 plan, and it does not include new company fundamentals (no guidance, trial, or regulatory updates).

Market effects

Sector

Minimal; single-company insider sale without accompanying sector/regulatory developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as risk management ahead of uncertain catalysts.

Key entities

  • issuer
    Ionis Pharmaceuticals Inc

    Subject of the Form 4 insider transaction; EVP Chief Development Officer sold shares under a 10b5-1 plan.

  • insider
    Holly B. Kordasiewicz

    EVP, Chief Development Officer who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IONS insider trading history →

Related articles

SEP 25
$IONSHighAI 8/10

Ionis Pharmaceuticals (IONS) Posted Two Positive Phase 3 Trial Readouts

Ionis Pharmaceuticals (IONS) reported positive Phase 3 trial results for two RNA-targeted drugs: sefaxersen, partnered with Roche, met its primary endpoint in IgA nephropathy, and ulefnersen, developed with Otsuka, achieved its main goal in FUS-ALS. These results could expand Ionis's market share and revenue, but pricing and regulatory risks remain.

simplywall.st3 min
SEP 23
$IONSHighAI 8/10

Ionis Phase 3 sefaxersen trial meets IgAN endpoint

Ionis Pharmaceuticals announced that its Phase 3 IMAgINATION trial for sefaxersen met its primary endpoint, showing a statistically significant and clinically meaningful reduction in urine protein at week 37 compared to placebo. The trial, conducted with Roche, remains blinded for a week-105 comparison of kidney function. Ionis may receive milestones and royalties if sefaxersen advances and sells.

mugglehead.com2 min
SEP 23
$IONSMedAI 8/10

Ionis Pharmaceuticals stock hits 52-week low at $44.20

Ionis Pharmaceuticals (IONS) stock hit a 52-week low of $44.20, trading at $44.24 with a $7.39B market cap. The stock has fallen 30.81% over the past year and 42% year-to-date. Analysts have mixed views, with price targets ranging from $54 to $105. Recent clinical trial results showed positive outcomes for Ulefnersen in FUS-ALS, but some analysts lowered price targets due to concerns about drug launches and trial results.

investing.com2 min
SEP 23
$IONSMedAI 8/10

BMO reiterates Ionis Pharmaceuticals stock rating on ALS drug data

BMO Capital reiterated a Market Perform rating and $54 price target for Ionis Pharmaceuticals (IONS) after positive ALS drug trial results. The stock is near its 52-week low, down 42% YTD. The study met primary endpoints, showing functional improvement and survival benefits. Analysts have mixed outlooks, with some lowering price targets due to recent setbacks.

investing.com2 min
SEP 23
$IONSMedAI 8/10

Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod

Roche and Ionis Pharmaceuticals reported positive Phase 3 trial results for sefaxersen, their RNA therapy for kidney disease, meeting the primary endpoint of reducing proteinuria. The drug showed a statistically significant improvement in urine protein-to-creatinine ratio compared to placebo, suggesting potential for accelerated FDA approval. Ionis' CEO indicated a regulatory filing would follow soon.

biospace.com2 min